Navigation Links
MediVet Biologics Launches Innovative Immunotherapy Trial for Canine Cancer
Date:7/11/2017

MediVet Biologics, a global leader in veterinary biologic solutions for pets announced today in partnership with the Veterinary Cancer Group (Los Angeles, CA) a trial for dogs stricken with cancer. The trial involves a breakthrough strategy of combining a personalized immunotherapy vaccine with specialty cancer standards of care.

K9ACV is a service provided by MediVet Biologics which allows for an affordable personalized immunotherapy vaccine for canine cancer. The immunotherapy cancer vaccine was developed by MediVet Biologics in partnership with researchers from the University of Kentucky Markey Cancer Center.

Immunotherapy is a cutting-edge strategy designed to assist the patient’s own immune system to work harder and more efficiently to attack cancer from within.

K9ACV is being studied by the veterinarian oncology team at Veterinary Cancer Group to be used in conjunction with current treatment strategies such as chemotherapy and radiation. The goal, is to study a multi modal approach to canine cancer to see if it can offer better outcomes when patients are in various stages of disease.

Greater than 50% of dogs over the age of ten will develop cancer and early detection is often difficult. The trial is now open and available to owners of canine patients with any form of cancer in the Orange County, San Fernando Valley & Los Angeles California areas.

In late 2016, an initial paper was published on the vaccine service and the company just finished an additional trial utilizing the vaccine for cancer patients at Kansas State University College of Veterinary Medicine.

Thomas Masterson, VP of Business Development, MediVet Biologics, “We have already had tremendous success utilizing K9ACV on patients who were not candidates for specialty cancer care. Our hope is that by combining our immunotherapy treatment with other established methodologies of canine oncology care we can make this service available to more patients in need and offer increased survival for the patient. We are fortunate to have partnered with a progressive group of oncologists such as the team at VCG.”    

About MediVet Biologics

MediVet Biologics is a animal health company focused on providing innovative strategies to fight diseases and redefine pet healthcare. Since 2010 the company has provided services to a network of thousands of progressive veterinarians such as Actistem™ Stem Cell Therapy and other biologic treatments designed to rebuild and repair processes naturally without dependency on drugs. Each product and service is designed to offer alternatives to improve the lives of pets and their owners.
http://www.medivetbiologics.com

Read the full story at http://www.prweb.com/releases/2017/07/prweb14494704.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. MediVet Biologics to Host Biologics Symposium at Western Veterinary Conference
2. MediVet Biologics to Present University Study on Canine Stem Cells during 2016 North American Veterinary Conference
3. MediVet Biologics Completes Initial Cancer Trial Utilizing Immunotherapy
4. MediVet Biologics Announces Appointment of Jeff Baker as New Chief Operating Officer
5. MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas
6. MediVet Biologics Acquires Exclusive Patent License from Kansas State University
7. MediVet Biologics adds Merritt Veterinary Supplies, Inc. as a Distribution Partner of Veterinary Stem Cell and other Biologic treatment options.
8. MediVet Biologics to Host Progressive Summit on Animal Health Biologic Treatment Options at 2015 AVMA Convention in Boston
9. World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction
10. MediVet America Secures Exclusive Worldwide License with Nanofiber Veterinary
11. Catalent Biologics Announces Collaboration with Therachon, Switzerland, to Advance Clinical Development of Innovative Protein Therapy for Achondroplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... CALIF. (PRWEB) , ... October 10, 2017 , ... San ... part of its corporate rebranding initiative announced today. The bold new look is ... reach, as the company moves into a significant growth period. , It will also ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
Breaking Biology Technology:
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):